Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 8
Submit an article Journal homepage
2,421
Views
5
CrossRef citations to date
0
Altmetric
Hematology

Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States

Jun SuSanofi, Cambridge, MA, USA; Correspondence[email protected]
View further author information
,
Lauren C. BylsmaEpidStrategies, A Division of ToxStrategies, Inc, Ann Arbor, MI, USA; View further author information
,
Xiaohui JiangEpidStrategies, A Division of ToxStrategies, Inc, Ann Arbor, MI, USA; View further author information
,
Jaime Morales AriasSanofi, Cambridge, MA, USA; View further author information
,
Nisha JainSanofi, Cambridge, MA, USA; View further author information
&
Robert J. NordykeBeta6 Consulting Group, Los Angeles, CA, USAView further author information
Pages 902-907 | Received 10 Mar 2020, Accepted 20 Apr 2020, Published online: 20 May 2020

References

  • Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–466.
  • Berentsen S. Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease. Semin Hematol. 2018;55(3):141–149.
  • Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980;56(3):409–416.
  • Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–1121.
  • Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):226–231.
  • Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol. 2018;181(3):320–330.
  • Kamesaki T, Nishimura J, Wada H, et al. Clinical characteristics, treatment patterns, and thromboembolic risk of patients with cold agglutinin disease (CAD) in Japan. HemaSphere. 2019;3(Suppl. 1):169.
  • Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020. DOI:10.1002/rth2.12333
  • Bylsma LC, Ording AG, Frøslev T, et al. The occurrence and survival of cold agglutinin disease in Denmark. HemaSphere. 2018;2(Suppl. 1):513.
  • Mullins M, Jiang X, Bylsma LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. Blood Adv. 2017;1(13):839–848.
  • Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
  • Caveney AF, Silbergleit R, Frederiksen S, et al. Resource utilization and outcome at a university versus a community teaching hospital in tPA treated stroke patients: a retrospective cohort study. BMC Health Serv Res. 2010;10(1):44.
  • Reed SD, Blough DK, Meyer K, et al. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology. 2001;57(2):305–314.
  • Burke L, Khullar D, Orav EJ, et al. Do academic medical centers disproportionately benefit the sickest patients? Health Aff (Millwood). 2018;37(6):864–872.
  • Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922–929.
  • Muus P, Langemeijer S, Hochsmann B, et al. Patient-reported outcomes and healthcare resource utilization before and during treatment with eculizumab: results from the International Paroxysmal Nocturnal Hemoglobinuria Registry. Poster session presented at: European Hematology Association 22nd Annual Congress; 2017 Jun 22–25; Madrid, Spain.
  • Peffault De Latour R, Huynh L, Ivanova JI, et al. A retrospective chart review to assess burden of illness among patients with severe aplastic anemia with insufficient response to immunosuppressive therapy. Blood. 2017;130(Suppl. 1):678.
  • Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633–641.
  • Placzek H, Xu Y, Mu Y, et al. Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J Manag Care Spec Pharm. 2015;21(12):1106–1112.
  • Cohen B, Balcells C, Hotchkiss B, et al. A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008–2015. Orphanet J Rare Dis. 2018;13(1):210.
  • Belk KW, Craver CW. Hospital-based utilization in patients with atypical hemolytic uremic syndrome. Value Health. 2014;17(3):A61.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.